The Sweat Solution: Bypassing the Kidneys to Break the Heart Failure Trap

NEWTON, Mass. – November 05, 2026

For millions of Americans living with heart failure, the most terrifying sensation isn't a sudden, sharp chest pain. It is the slow, suffocating creep of fluid building up in their lungs, abdomen, and limbs. It is the feeling of drowning from the inside out.

Congestion, as the medical community clinically terms this fluid overload, drives more than one million hospital admissions in the United States every single year. The standard medical response has remained largely unchanged for decades: flood the patient's system with high-dose intravenous diuretics to force the kidneys to excrete the excess water. But this approach is a blunt instrument, and over time, it fundamentally breaks the very organs it relies upon.

Today, AQUAPASS Medical, a medical technology company based in Newton, Massachusetts, announced pivotal clinical trial results that could fundamentally alter this grim trajectory. The data from their REFORM-HF trial suggests that the solution to diuretic resistance might not lie in pushing the kidneys harder, but in bypassing them entirely—by hacking the human body's eccrine sweat glands.

The Diuretic Trap and the Kidneys' Breaking Point

To understand the significance of the AQUAPASS ECCON System, one must first understand the systemic failure of our current standard of care.

In the later stages of heart failure, a vicious cycle known as cardiorenal syndrome takes hold. As the heart pumps less effectively, blood flow to the kidneys diminishes. In response, the kidneys, sensing a drop in pressure, hoard water and sodium. Physicians counter this by prescribing loop diuretics. While initially effective, prolonged use of these drugs inevitably leads to diuretic resistance. The kidneys simply stop responding.

This leaves physicians with an impossible choice: continue administering toxic levels of drugs that no longer work, or discharge the patient while they are still congested. The data reveals the tragic outcome of this dilemma. More than 40 percent of heart failure patients are discharged from the hospital with residual congestion, practically guaranteeing their return. Consequently, 25 percent of these patients are readmitted within 30 days, fueling a multi-billion-dollar revolving door that profits no one and exhausts the patients trapped within it.

"Fluid overload remains one of the most difficult problems we manage in heart failure," said Dr. Scott Feitell, Director of Heart Failure and the Intensive Care Unit at Novant Health Presbyterian Hospital and the National Principal Investigator for the REFORM-HF trial.

The trial deliberately targeted this most vulnerable demographic. According to the data presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026, more than 75 percent of the patients enrolled in REFORM-HF had Stage 3 or 4 chronic kidney disease alongside their diuretic-resistant heart failure. These are the patients for whom the medical system has historically run out of answers.

Hacking the Eccrine System

The AQUAPASS ECCON System takes a radically different approach. It is a non-invasive, wearable garment designed to stimulate the body's eccrine sweat glands, drawing fluid directly from the extravascular space and out through the skin.

The physiological premise is both elegant and complex. Eccrine sweat is primarily a dilute electrolyte solution. While it contains sodium, potassium, and chloride, the concentration of these ions is significantly lower than in blood plasma. By forcing the body to sweat at high volumes, the ECCON device can remove massive amounts of water without immediately triggering the severe electrolyte crashes often associated with aggressive intravenous diuretics.

The results from the REFORM-HF trial (NCT06360380) are striking. The trial met its primary effectiveness endpoint by a massive margin. Patients using the ECCON System achieved a mean additional net fluid loss of 785 grams across two treatment days compared to their own baseline control days, easily surpassing the 500-gram success threshold (p<0.0001).

Perhaps more importantly, the device delivered a greater than sevenfold increase in net fluid loss with a 91 percent responder rate. Crucially, there were no device-related adverse events reported.

"In REFORM-HF, the ECCON System delivered consistent, meaningful fluid removal through the skin, regardless of kidney function," Dr. Feitell noted. "These are very exciting results for heart failure patients who often have few options left."

Until now, the alternatives for diuretic-resistant patients have been highly invasive and fraught with complications. Mechanical ultrafiltration systems, such as the Aquadex SmartFlow, require central or peripheral intravenous access to physically filter fluid from the blood. While effective, it is an invasive procedure tethering patients to clinical settings. Peritoneal dialysis, another alternative, requires a catheter surgically implanted into the abdomen. Experimental lymphatic drainage therapies also rely on invasive catheterizations.

A wearable, non-invasive garment that can be utilized without surgical intervention represents a paradigm shift, moving the locus of care away from the intensive care unit and potentially into the outpatient clinic or the patient's own home.

Navigating the Regulatory Labyrinth

Proving a device works in a clinical trial is only half the battle; the other half is navigating the labyrinthine corridors of federal regulation.

"REFORM-HF was designed to answer a clear question, and the trial met its primary endpoint by a strong margin," said Dr. Noam Josephy, Chief Executive Officer of AQUAPASS. "We are grateful to the patients, investigators and site teams who put Patients First at every step of this trial. We are now focused on our De Novo submission to the FDA."

The De Novo pathway is specifically reserved for novel medical devices that are low-to-moderate risk but have no existing market predicate. Because the ECCON System's mechanism of action—therapeutic sweating for heart failure—is entirely unprecedented, it cannot simply be cleared by comparing it to an older device.

However, AQUAPASS holds a distinct advantage. The FDA has already granted the technology two Breakthrough Device Designations. This status is reserved for technologies that offer a clear advantage over existing treatments for life-threatening or irreversibly debilitating conditions. It places the ECCON System on an expedited review track, theoretically obligating the FDA to prioritize its assessment.

The Economics of Access and Inequity

Yet, as with all medical breakthroughs in the American healthcare system, regulatory clearance does not guarantee patient access. The true test of the ECCON System will be whether the Centers for Medicare & Medicaid Services (CMS) agrees to pay for it.

Historically, the gap between FDA authorization and CMS coverage could stretch for years, leaving innovative therapies accessible only to the wealthy or those lucky enough to enroll in clinical trials. This is the systemic inequity that plagues American medicine: a two-tiered system where survival often depends on your zip code and your insurance carrier.

There is a glimmer of hope on the policy front. CMS recently introduced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway. Designed specifically for FDA-designated Breakthrough Devices, RAPID aims to slash the time from FDA authorization to Medicare national coverage down to just 60 to 90 days. If AQUAPASS has successfully aligned its clinical trial endpoints with CMS requirements, the ECCON System could become a test case for this new, accelerated pathway.

If the technology is cleared and covered, the economic implications are profound. Reducing the one million annual heart failure admissions by even a fraction would save the healthcare system billions of dollars. But the true value cannot be measured on a hospital ledger. It is measured in the quiet dignity of a patient who can finally breathe easily, sleep through the night, and stay in their own home rather than a hospital ward.